- $3.27bn
- $2.44bn
- $218.71m
Ideaya rises as it starts early-stage trial of combination of cancer drugs
Brief: Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of Ide034, A Potential First-In-Class B7h3/Ptk7 Bispecific Top1 Adc
Brief: Ideaya Biosciences Announces Appointment Of Dr. Theodora (Theo) Ross, M.D., Ph.D., As Chief Development Officer
IDEAYA Q4 profit slightly beats estimates
Brief: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Brief: Ideaya Biosciences Completes Targeted Full Enrollment In Randomized Pivotal Phase 2/3 Trial (Optimum-02) Of Darovasertib In Combination With Crizotinib
Brief: Ideaya Biosciences Announces Ind Submission For Ide574
U.S. STOCKS ON THE MOVE-Walt Disney, BankUnited, copper miners
U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources
U.S. STOCKS ON THE MOVE-Barrick Mining, Tesla, Accenture
Ideaya rises as FDA clears trial for experimental cancer drug
Brief: Ideaya Biosciences Announces Clearance For IDE034
IDEAYA Biosciences Q3 net income beats estimates
U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic
U.S. RESEARCH ROUNDUP-Block, Morgan Stanley, W R Berkley
U.S. STOCKS ON THE MOVE-Arm Holdings, silver miners, Zions Bancorp
U.S. STOCKS ON THE MOVE-Apple, Zoom, Arm Holdings